Synthetic Biologics, Inc (SYN) saw its loss narrow to $27.26 million, or $0.29 a share for the year ended Dec. 31, 2016. In the previous year period, the company reported a loss of $43.74 million, or $0.54 a share. The company has not recorded any revenues for the current as well as previous year.
Operating loss for the year was $39.25 million, compared with an operating loss of $40.98 million in the previous year.
"2016 was a transformative and momentum-building year for Synthetic Biologics," said Jeffrey Riley, president and chief executive officer. "In the past 12 months, we announced positive proof-of-concept clinical results for our lead microbiome-focused programs representing significant milestones for our company. Most recently, we announced positive topline results from ribaxamase’s global Phase 2b proof-of-concept clinical trial which achieved its primary endpoint by demonstrating a statistically significant reduction in the incidence of primary C. difficile infection (CDI) compared to placebo, positioning ribaxamase as a vanguard amongst microbiome-based therapeutics pursuing clinical development for this indication in Phase 2 trials or later. Data from this study also demonstrated that ribaxamase significantly reduced the incidence of new colonization by vancomycin-resistant enterococci (VRE) compared to placebo, potentially expanding the utility of our compound as a first line of defense against the development of antimicrobial resistance (AMR) in the gut microbiome. We believe ribaxamase may represent a disruptive yet simple approach to antibiotic therapy that may directly lead to more effective and efficient use of antibiotics."
Working capital drops significantly
Synthetic Biologics, Inc has witnessed a decline in the working capital over the last year. It stood at $1.81 million as at Dec. 31, 2016, down 87.72 percent or $12.95 million from $14.76 million on Dec. 31, 2015. Current ratio was at 1.09 as on Dec. 31, 2016, down from 1.95 on Dec. 31, 2015.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
